Physician profile
Isabelle H Eustice
NPI 1821021080
$383.38
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $293 · 2020: $22.97 · 2022: $27.81 · 2023: $40.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $40.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $40.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $138.40 | 2019-2020 | |
| Allergan, INC. | $69.16 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $40.00 | 2023 | |
| Indivior INC. | $27.81 | 2022 | |
| Alkermes, INC. | $23.68 | 2019 | |
| Acadia Pharmaceuticals INC | $22.29 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $17.88 | 2019 | |
| Neurocrine Biosciences, INC. | $16.65 | 2019 | |
| Vanda Pharmaceuticals INC. | $14.13 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.38 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabelle Eustice listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.